Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly Improves EFS in PD-L1-positive, Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 30, 2026 157 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTRUM-006 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR 5 Tips to Move Beyond the Bedside May 17, 2021 Merging the Histologic and Molecular Data Into an Integrated Score Significantly... October 11, 2021 Fertility Preservation Safe for Young Women with Breast Cancer December 22, 2020 Reunión anual de la American Society of Clinical Oncology de 2023:... June 2, 2023 Load more HOT NEWS A new year of expanding research horizons PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... COVID-19: “We’ve got so much on our plates” Intracranial Efficacy of Pembrolizumab in Patients with Brain Metastases
